Proteins in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 583 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 168 drugs. Proteins In Oncology Drug Pipeline Update lists ... \| read more...	$5,621.25
RANKL Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... and plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C ... \| read more...	$5,621.25
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... cell receptor signaling. There are today 219 companies plus partners developing 270 T cell receptor pathway targeting drugs in 972 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number ... \| read more...	$5,621.25
Targeting Tight Junctions in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... consisting of many different proteins that form large complexes. There are today 73 companies plus partners developing 65 tight junction targeting drugs in 285 developmental projects in cancer. In addition, there is 1 suspended drug ... \| read more...	$3,746.25
The MAPK Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... There are today 213 companies plus partners developing 277 The MAPK signaling pathway targeting drugs in 1050 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs ... \| read more...	$5,621.25
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... in 1016 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 144 drugs. Tnf-Alpha Signaling Pathway In Oncology Drug ... \| read more...	$5,621.25
Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... for the cell trafficking and thus are vital for protective host response. In addition, chemokines regulate plethora of biological processes of hematopoietic cells to lead cellular activation, differentiation and survival. There are today 151 companies ... \| read more...	$5,621.25
Cough, Cold and Allergy (Hay Fever) Remedies in Finland 4/22/2013 \| published by: Euromonitor International ... switches take place in previous years, which increased self-medication and boosted OTC sales. Moreover, allergy levels in Finland are increasing, and cold winters also tend to give a boost to sales. The winter at the ... \| read more...	$900.00
Digestive Remedies in Finland 4/22/2013 \| published by: Euromonitor International ... pump inhibitors in particular saw several switches from 2009. As a result, self-medication amongst Finns has increased, as they have been looking for help for digestion problems, which seem to be increasing in the country. ... \| read more...	$900.00
TSLP Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... cells upon pathogen stimulation. TSLP can also activate dendritic cells, CD4+ T cells and CD8+ T cells. TSLP not only activate the JAK/STAT pathway but also induce phosphorylation of other signaling molecules including PI3K/Akt, ERK1/2 ... \| read more...	$5,621.25
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... signal transducer in both physiologic and pathologic angiogenesis. The binding of VEGF to VEGFR-2 leads to a cascade of different signaling pathways, resulting in the up-regulation of genes involved in mediating the proliferation and migration ... \| read more...	$5,621.25
Emergency Contraception in Finland 4/22/2013 \| published by: Euromonitor International ... shows seasonality in Finland, as sales increase in the warmer spring and summer months in particular, peaking after the May Day celebrations and after the Midsummer festival in June. According to the Family Federation, the ... \| read more...	$900.00
Analytical Tool - Peptides in Oncology 4/22/2013 \| published by: BioSeeker Group AB ... same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of ... \| read more...	$11,625.00
NRT Smoking Cessation Aids in Finland 4/22/2013 \| published by: Euromonitor International ... new ban came into force prohibiting the display of tobacco products in retail outlets. Consumers have the right to see a catalogue of the products available and receive information about them and their prices; however, ... \| read more...	$900.00
Analytical Tool - Prostate Cancer 4/22/2013 \| published by: BioSeeker Group AB ... map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies ... \| read more...	$11,625.00
Cytokine Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... accumulated number of ceased drugs over the last years amount to another 7 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ... \| read more...	$3,746.25
Epigenetic Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... autoimmunity, diabetes, or neurological disorders. Recent research has identified the set of enzymes and chromatin-binding proteins responsible for regulating chromatin structure. These enzymes and binding proteins form the cell’s toolkit for epigenetic regulation by opening ... \| read more...	$3,746.25
Apoptosis in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... cancer cells. There are today 282 companies plus partners developing 277 apoptotic drugs in 1179 developmental projects in cancer. In addition, there are 9 suspended drugs and the accumulated number of ceased drugs over the ... \| read more...	$5,621.25
Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... of the alpha chain of Fc epsilon RI. The activation pathways are regulated both positively and negatively by the interactions of numerous signaling molecules. These mediators and cytokines contribute to inflammatory responses. There are today ... \| read more...	$5,621.25
Gap Junctions in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 'hemichannels', each containing six connexins, contributed by each neighboring cell. These channels permit the direct transfer of small molecules including ions, amino acids, nucleotides, second messengers and other metabolites between adjacent cells. Gap junctional communication ... \| read more...	$5,621.25
Viral Carcinogenesis Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), human T-cell lymphotropic virus (HTLV-1) and Kaposi's associated sarcoma virus (KSHV) contribute to 10-15% of the cancers worldwide. Via expression of many potent oncoproteins, these tumor ... \| read more...	$5,621.25
GnRH Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... and FSH. There are today 137 companies plus partners developing 152 GnRH signaling pathway targeting drugs in 526 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount ... \| read more...	$5,621.25
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... today 55 companies plus partners developing 47 Hedgehog pathway targeting drugs in 225 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years ... \| read more...	$1,871.25
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... are today 103 companies plus partners developing 109 Wnt pathway targeting drugs in 385 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last ... \| read more...	$3,746.25
Analytical Tool - Breast Cancer 4/22/2013 \| published by: BioSeeker Group AB ... map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies ... \| read more...	$11,625.00

< prev 4 5 6 7 8 9 10 11 12 13 next >